Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
KHAN Technology Transfer Fund I is an early-stage life sciences venture fund based in Europe, founded to create value through cooperative drug development partnerships with academic innovators. Established with a focus on translating academic projects into commercially viable assets, the fund particularly targets first-in-class therapies for markets with high unmet medical needs. The fund's approach emphasizes collaboration with academic institutions, including access to the Max Planck Society, to facilitate the development of drug assets.
Currently, KHAN Technology Transfer Fund I manages assets totaling €70 million and has funded over 50 scientific assets and more than 10 startups. The firm operates primarily in the biotech and healthcare sectors, focusing on pre-seed to Series A funding stages. Their notable milestones include establishing partnerships with leading academic institutions to enhance the commercialization potential of early-stage innovations.
KHAN Technology Transfer Fund I invests in early-stage life sciences projects, specifically targeting first-in-class therapeutics. The fund emphasizes innovative technology transfer in drug discovery and aims to address the gap between academia and industry. It collaborates with academic institutions to facilitate the development of drug assets, providing flexible funding and support to structure projects and build companies. This approach allows the fund to engage with projects that may not yet have fully validated assets or complete teams at the outset.
The fund's investment strategy includes a focus on pre-seed, seed, seed+ (extension), and Series A funding stages. By concentrating on biotech and healthcare sectors, KHAN Technology Transfer Fund I seeks to invest in projects that have the potential to meet significant medical needs. Their thesis revolves around translating academic research into commercially viable products, particularly in areas where there is a lack of effective therapies.
KHAN Technology Transfer Fund I has funded over 50 scientific assets and more than 10 startups. While specific names and descriptions of portfolio companies are not provided, the fund's focus on early-stage life sciences indicates that its portfolio likely includes innovative projects in biotech and healthcare. The emphasis on first-in-class therapeutics suggests that the fund is involved with companies developing novel drug candidates aimed at addressing high unmet medical needs.
The fund's collaborative approach with academic institutions positions it to support startups that are translating cutting-edge research into practical applications. This strategy enhances the potential for successful outcomes in their portfolio companies.
Michael Hamacher - Managing Partner/CFO. Michael has extensive experience in venture capital and finance, focusing on life sciences investments.
Bert Klebl - Managing Partner/CEO. Bert has a strong background in biotech and has led numerous successful investments in the sector.
Peter Nussbaumer - Managing Partner. Peter brings expertise in drug development and has a track record of working with academic institutions.
Johannes Bange - Partner. Johannes specializes in early-stage investments and has a keen interest in innovative healthcare solutions.
Markus Peters - Partner (KHAN-II). Markus has a background in venture capital and focuses on supporting biotech startups.
Michael Krebs - Managing Partner (KHAN-I). Michael has significant experience in the life sciences sector and is involved in strategic decision-making.
Jan Adams - Partner (KHAN-II). Jan has expertise in technology transfer and works closely with academic partners.
To pitch KHAN Technology Transfer Fund I, startups should visit their website at khan-i.de. The fund prefers pitches that clearly outline the project's potential impact, the technology involved, and any academic partnerships. Response times may vary, so founders should be prepared for follow-up discussions.
As of October 2023, KHAN Technology Transfer Fund I has been actively engaging with academic institutions, including the Max Planck Society, to facilitate the development of drug assets. The fund continues to focus on early-stage life sciences projects, particularly in the biotech and healthcare sectors.
Recent activities include funding new scientific assets and expanding partnerships with universities to enhance their portfolio of innovative therapeutics.
What are the investment criteria for KHAN Technology Transfer Fund I?
The fund focuses on early-stage life sciences projects, particularly those targeting first-in-class therapeutics. It invests in pre-seed, seed, seed+ (extension), and Series A funding stages.
How can startups apply or pitch to KHAN Technology Transfer Fund I?
Startups can submit their pitches through the fund's website at khan-i.de. Specific application forms or additional details may be available on the site.
What makes KHAN Technology Transfer Fund I different from other venture funds?
The fund emphasizes collaboration with academic institutions and innovative technology transfer in drug discovery, which allows it to bridge the gap between academia and industry effectively.
What is the geographic scope of KHAN Technology Transfer Fund I?
The fund primarily operates in Europe, focusing on life sciences projects that have the potential for significant impact in the healthcare sector.
What kind of post-investment involvement does KHAN Technology Transfer Fund I have?
The fund provides flexible funding and support to help structure projects and build companies, often without requiring fully validated assets or complete teams at the outset.
What is the typical check size for investments made by KHAN Technology Transfer Fund I?
While specific check sizes are not disclosed, the fund focuses on early-stage investments, which typically range from pre-seed to Series A funding amounts.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.